Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam?
biliary tract cancer
hepatocellular carcinoma
immunotherapy
oncolytic virus
pancreatic cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
14
12
2019
revised:
13
02
2020
accepted:
14
02
2020
pubmed:
5
3
2020
medline:
15
5
2021
entrez:
5
3
2020
Statut:
ppublish
Résumé
Traditional therapies have limited efficacy in hepatocellular carcinoma, pancreatic cancer, and biliary tract cancer, especially for advanced and refractory cancers. Through a deeper understanding of antitumor immunity and the tumor microenvironment, novel immunotherapies are becoming available for cancer treatment. Oncolytic virus (OV) therapy is an emerging type of immunotherapy that has demonstrated effective antitumor efficacy in many preclinical studies and clinical studies. Thus, it may represent a potential feasible treatment for hard to treat gastrointestinal (GI) tumors. Here, we summarize the research progress of OV therapy for the treatment of hepato-bilio-pancreatic cancers. In general, most OV therapies exhibits potent, specific oncolysis both in cell lines in vitro and the animal models in vivo. Currently, several clinical trials have suggested that OV therapy may also be effective in patients with refractory hepato-bilio-pancreatic cancer. Multiple strategies such as introducing immunostimulatory genes, modifying virus capsid and combining various other therapeutic modalities have been shown enhanced specific oncolysis and synergistic anti-cancer immune stimulation. Combining OV with other antitumor therapies may become a more effective strategy than using virus alone. Nevertheless, more studies are needed to better understand the mechanisms underlying the therapeutic effects of OV, and to design appropriate dosing and combination strategies.
Identifiants
pubmed: 32130786
doi: 10.1002/cam4.2949
pmc: PMC7196045
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2943-2959Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Res. 2003 Jul 1;63(13):3605-11
pubmed: 12839948
Gene Ther. 2009 Oct;16(10):1223-33
pubmed: 19587709
Clin Cancer Res. 2004 Aug 15;10(16):5299-312
pubmed: 15328165
Clin Cancer Res. 2009 Mar 1;15(5):1730-40
pubmed: 19223497
Nat Biotechnol. 2012 Jul 10;30(7):658-70
pubmed: 22781695
J Clin Invest. 2005 Feb;115(2):379-87
pubmed: 15690085
AJR Am J Roentgenol. 2009 Jan;192(1):279-87
pubmed: 19098211
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43
pubmed: 8097319
Ann Surg Oncol. 2008 Aug;15(8):2329-35
pubmed: 18454298
Mol Ther. 2012 Apr;20(4):749-58
pubmed: 22186794
Gene Ther. 2000 May;7(10):867-74
pubmed: 10845725
Virology. 1988 Sep;166(1):41-51
pubmed: 2842955
Mol Ther. 2012 Apr;20(4):759-68
pubmed: 22233582
Mol Ther. 2007 Aug;15(8):1522-30
pubmed: 17457318
Gene Ther. 2001 Feb;8(4):308-15
pubmed: 11313805
Mol Ther. 2006 Sep;14(3):361-70
pubmed: 16905462
Blood. 2016 May 26;127(21):2575-86
pubmed: 26941401
J Gen Virol. 2013 Mar;94(Pt 3):465-481
pubmed: 23239572
Oncotarget. 2018 Apr 20;9(30):21348-21358
pubmed: 29765544
J Virol. 2018 Nov 12;92(23):
pubmed: 30232179
Mol Ther. 2006 May;13(5):882-90
pubmed: 16569513
Cancer Gene Ther. 2015 Dec;22(12):591-6
pubmed: 26584530
Nature. 2011 Aug 31;477(7362):99-102
pubmed: 21886163
Gene Ther. 2009 Sep;16(9):1077-87
pubmed: 19474810
Nat Med. 2013 Mar;19(3):329-36
pubmed: 23396206
Mol Ther. 2008 Sep;16(9):1637-42
pubmed: 18628758
J Biol Chem. 2001 Jul 20;276(29):27058-63
pubmed: 11359776
Cancer Res. 2004 Jul 15;64(14):4919-26
pubmed: 15256464
Hum Gene Ther. 2008 Jun;19(6):635-47
pubmed: 18533893
Hepatology. 2004 May;39(5):1371-81
pubmed: 15122766
Oncogene. 2004 Jan 15;23(2):457-64
pubmed: 14724574
EMBO J. 1998 Jun 15;17(12):3351-62
pubmed: 9628872
Clin Cancer Res. 2003 Mar;9(3):1218-23
pubmed: 12631628
Oncogene. 2010 Jul 8;29(27):3990-6
pubmed: 20473328
Mol Ther. 2001 Apr;3(4):431-7
pubmed: 11319903
J Immunol. 2008 May 1;180(9):5771-7
pubmed: 18424693
Methods Mol Biol. 2015;1317:343-57
pubmed: 26072416
Cancer Res. 2003 Aug 1;63(15):4434-40
pubmed: 12907616
Cancer Gene Ther. 2006 Mar;13(3):326-34
pubmed: 16138120
Science. 1997 Feb 28;275(5304):1320-3
pubmed: 9036860
PLoS Med. 2007 Dec;4(12):e353
pubmed: 18162040
Gut. 2018 Mar;67(3):562-573
pubmed: 27902444
Drug Discov Ther. 2015 Oct;9(5):363-71
pubmed: 26632545
Crit Rev Oncol Hematol. 2017 Feb;110:106-116
pubmed: 28109400
Mol Cancer. 2014 Apr 13;13:82
pubmed: 24725816
Immunobiology. 2018 Apr - May;223(4-5):432-442
pubmed: 29246400
Mol Ther Oncolytics. 2015;2:
pubmed: 26462293
Hepatology. 2014 Jan;59(1):343-6
pubmed: 23836532
Clin Cancer Res. 2011 Feb 1;17(3):581-8
pubmed: 21106728
Oncol Rep. 2013 Aug;30(2):833-41
pubmed: 23727990
Clin Cancer Res. 2009 Jul 1;15(13):4374-4381
pubmed: 19509134
Invest New Drugs. 2015 Jun;33(3):761-74
pubmed: 25693885
Cancer Gene Ther. 2007 Jun;14(6):533-42
pubmed: 17415379
Oncotarget. 2017 Apr 20;8(42):71489-71499
pubmed: 29069721
Clin Cancer Res. 2006 May 15;12(10):3152-7
pubmed: 16707615
Cancer Res. 2003 Mar 15;63(6):1262-9
pubmed: 12649186
Cancer Cell Int. 2014 Sep 19;14(1):83
pubmed: 25360068
Clin Cancer Res. 2015 Jan 15;21(2):405-16
pubmed: 25416195
Cancer Gene Ther. 2009 May;16(5):453-61
pubmed: 19096445
Hum Gene Ther. 2013 May;24(5):554-64
pubmed: 23550539
Science. 1998 Nov 13;282(5392):1332-4
pubmed: 9812900
Vet Res. 2007 Mar-Apr;38(2):299-318
pubmed: 17296158
J Surg Oncol. 2017 Jul;116(1):94-103
pubmed: 28407327
Mol Ther. 2012 Feb;20(2):339-46
pubmed: 22146341
Cancers (Basel). 2018 May 25;10(6):
pubmed: 29799479
Lancet Oncol. 2008 Jun;9(6):533-42
pubmed: 18495536
Int J Oncol. 2005 Oct;27(4):901-6
pubmed: 16142304
Cell Res. 2003 Dec;13(6):481-9
pubmed: 14728805
J Infect Dis. 1994 Nov;170 Suppl 1:S32-41
pubmed: 7930752
Mol Cancer Ther. 2009 Jan;8(1):141-51
pubmed: 19139123
Nat Immunol. 2004 Dec;5(12):1266-74
pubmed: 15502830
Cancer Lett. 2009 Nov 18;285(1):89-98
pubmed: 19481338
Oncogene. 2001 Nov 26;20(54):7824-35
pubmed: 11753665
Science. 1996 Oct 18;274(5286):373-6
pubmed: 8832876
World J Gastroenterol. 2016 Jan 7;22(1):326-37
pubmed: 26755879
J Biol Chem. 1994 May 13;269(19):13836-42
pubmed: 8188661
Clin Pharmacol Ther. 2010 Nov;88(5):620-5
pubmed: 20881957
Cancer Gene Ther. 2011 Aug;18(8):598-608
pubmed: 21701532
Int J Oncol. 2006 Nov;29(5):1319-29
pubmed: 17016667
Chin Med J (Engl). 2014;127(12):2350-6
pubmed: 24931255
Mol Ther. 2016 Jun;24(6):1150-1158
pubmed: 27039845
Int J Cancer. 2006 Jul 15;119(2):432-40
pubmed: 16477640
Cancer Gene Ther. 2011 Mar;18(3):167-75
pubmed: 21102422
Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):843-8
pubmed: 9023344
Clin Cancer Res. 2003 Feb;9(2):555-61
pubmed: 12576418
Cancer Med. 2020 May;9(9):2943-2959
pubmed: 32130786
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
Clin Cancer Res. 2017 Oct 1;23(19):5846-5857
pubmed: 28536305
Hum Gene Ther. 1999 Feb 10;10(3):385-93
pubmed: 10048391
Medicine (Baltimore). 2016 Dec;95(49):e5541
pubmed: 27930550
Mol Ther. 2007 Sep;15(9):1686-93
pubmed: 17579581
J Surg Res. 2009 Nov;157(1):e63-70
pubmed: 19345377
Mol Cell Biol. 1992 Jun;12(6):2570-80
pubmed: 1317006
Clin Exp Immunol. 2006 Nov;146(2):344-53
pubmed: 17034588
Cancer Gene Ther. 2002 Dec;9(12):979-86
pubmed: 12522437
Mol Cancer. 2011 Feb 21;10:20
pubmed: 21338484
Cancer Res. 2007 Mar 15;67(6):2840-8
pubmed: 17363607
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
Clin Cancer Res. 2007 May 15;13(10):3043-50
pubmed: 17505007
J Biomed Sci. 2012 Feb 09;19:20
pubmed: 22321574
Clin Cancer Res. 2007 Jan 1;13(1):316-22
pubmed: 17200370
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4640-5
pubmed: 16537421
Int J Exp Pathol. 2001 Apr;82(2):65-76
pubmed: 11454099
J Cancer Res Clin Oncol. 2012 Apr;138(4):657-70
pubmed: 22237452
Mol Ther. 2010 Feb;18(2):429-34
pubmed: 19935775
Cancer Cell. 2004 Dec;6(6):611-23
pubmed: 15607965
PLoS One. 2011;6(7):e21307
pubmed: 21814544
Hepatogastroenterology. 2003 Nov-Dec;50(54):1847-53
pubmed: 14696417
Clin Cancer Res. 2000 Mar;6(3):798-806
pubmed: 10741699
Mol Oncol. 2011 Dec;5(6):545-54
pubmed: 22032823
Cancer Res. 2004 May 1;64(9):3265-70
pubmed: 15126368
Nat Med. 1997 Jun;3(6):639-45
pubmed: 9176490
Oncol Rep. 2009 Jun;21(6):1381-4
pubmed: 19424613
J Gastrointest Surg. 1999 Mar-Apr;3(2):127-31; discussion 132-3
pubmed: 10457334
Cancer Sci. 2016 Oct;107(10):1373-1379
pubmed: 27486853
Virology. 1999 Nov 25;264(2):298-318
pubmed: 10562494
Endocr Relat Cancer. 2010 Jan 29;17(1):F19-36
pubmed: 19779035
Oncotarget. 2015 May 30;6(15):13564-78
pubmed: 25980438
J Gastrointest Surg. 2000 Nov-Dec;4(6):580-8
pubmed: 11307092
Acta Pharmacol Sin. 2012 Dec;33(12):1441-58
pubmed: 22983389
Cancer Res. 1989 Sep 1;49(17):4682-9
pubmed: 2547513
Hepatology. 2006 Mar;43(3):425-34
pubmed: 16583461
Virus Res. 1996 Jan;40(1):17-31
pubmed: 8725118
Surgery. 2005 May;137(5):527-35
pubmed: 15855925
Cancer Sci. 2018 Mar;109(3):600-610
pubmed: 29288515
Oncogene. 2005 Nov 21;24(52):7775-91
pubmed: 16299537
Gene Ther. 2000 Jun;7(12):1019-26
pubmed: 10871750
J Gene Med. 2008 Sep;10(9):983-92
pubmed: 18618506
J Immunother. 2019 Jun;42(5):162-174
pubmed: 30933043
Cancer Res. 1997 Aug 1;57(15):3126-30
pubmed: 9242437
Mol Ther. 2015 Mar;23(3):602-8
pubmed: 25531693
Clin Cancer Res. 2015 Mar 15;21(6):1406-18
pubmed: 25391696
Mol Ther. 2010 Sep;18(9):1698-705
pubmed: 20606649
Clin Cancer Res. 2010 Jan 15;16(2):541-53
pubmed: 20068104
Mol Ther. 2004 Mar;9(3):368-76
pubmed: 15006603
Clin Cancer Res. 2006 Nov 1;12(21):6523-31
pubmed: 17085667